Serum amyloid A - A review

Molecular Medicine

Volumn 24, Issue 1, 2018, Pages

  Sack, George H ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

acute phase response (APR); amyloidosis; apolipoprotein; arthritis; atherosclerosis; cytokine; inflammation; lipopolysaccharide (LPS); liver; myeloid derived suppressor cells (MDSC); SAA; Serum amyloid A

Indexed keywords

C REACTIVE PROTEIN; CANAKINUMAB; COLLAGENASE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MATRIX METALLOPROTEINASE; METHOTREXATE; OPSONIN; ROSIGLITAZONE; SERUM AMYLOID A; TOLL LIKE RECEPTOR;

AA AMYLOIDOSIS; ACUTE PHASE RESPONSE; AMINO ACID SEQUENCE; ATHEROSCLEROSIS; CHOLESTEROL TRANSPORT; CHRONIC INFLAMMATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DIABETES MELLITUS; GRANULOMATOUS INFLAMMATION; HOST RESISTANCE; HUMAN; INTESTINE FLORA; LIPID METABOLISM; MASTITIS; METASTASIS; NONHUMAN; PATHOPHYSIOLOGY; PREMATURE LABOR; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SEPSIS; ANIMAL; LUNG SARCOIDOSIS; MAMMARY GLAND; MATERNAL WELFARE; METABOLISM; NEOPLASM; PHYSIOLOGY;

ACUTE-PHASE REACTION; ANIMALS; ATHEROSCLEROSIS; COLLAGENASES; HUMANS; LIPID METABOLISM; MAMMARY GLANDS, HUMAN; MATERNAL HEALTH; MATRIX METALLOPROTEINASES; NEOPLASMS; SARCOIDOSIS, PULMONARY; SERUM AMYLOID A PROTEIN;

EID: 85057222298     PISSN: 10761551     EISSN: 15283658     Source Type: Journal    
DOI: 10.1186/s10020-018-0047-0     Document Type: Review

References (279)

1. Abe-Dohmae S, Kato KH, Kumon Y, Hu W, Ishigami H, Iwamoto N, Okazaki M, Wu C-A, Tsujita M, Ueda K, Yokoyama S. Serum amyloid A generates high density lipoprotein with cellular lipid in an ABCA1- or ABCA7-dependent manner. J Lipid Res. 2006;47:1542-50.
2. Ancsin JB, Kisilevsky R. The heparin/heparin sulfate-binding site on apo-serum amyloid A. Implications for the therapeutic intervention of amyloidosis. J Bioi Chem. 1999;274:7172-81.
3. 2. J Lipid Res. 2010;51:743-54.
4. Atarashi K, Tanoue T, Ando M, Kamada N, Nagano Y, Narushima S, Suda W, Imaoka A, Steoyama H, Nagamori T, Ishikawa E, Shima T, Hara T, Kado S, Jinnohara T, Ohno H, Kondo T, Toyooka K, Watanabe E, Yokoyama S, Tokoro S, Mori H, Noguchi Y, Morita H, Ivanov II, Sugiyama T, Nunez G, Camp JG, Hattori M, Umesaki Y, Honda K. Th17 cell induction by adhesion of microbes to intestinal epithelial cells. Cell. 2015;163:357-80.
5. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: Inhibition of NF-κB activity through induction of IκB synthesis. Science. 1995;270:286-90.
6. Badolato R, Johnson JA, Wang JM, McVicar D, Xu LL, Oppenheim JJ, Kelvin OJ. Serum amyloid A induces calcium mobilization and chemotaxis of human monocytes by activating a pertussis toxin-sensitive signaling pathway. J Immunol. 1995;155:4004-10.
7. Badolato R, Wang JM, Murphy WJ, Lloyd AR, Michiel OF, Bausserman LL, Kelvin OJ, Oppenheim JJ. Serum amyloid A is a chemoattractant: induction of migration, adhesion, and tissue infiltration of monocytes and polymorphonuclear leukocytes. J Exp Med. 1994;180:203-9.
8. Baranova IN, Bocharov AV, Vishnyakova TG, Kurlander R, Chen Z, Fu D, Arias IM, Csako G, Patterson AP, Eggerman TL. CD36 is a novel serum amyloid A receptor mediating SAA binding and SAA-induced signaling in human and rodent cells. J Biol Chem. 2010;285:8492-506.
9. Baranova IN, Vishnyakova TG, Bocharov AV, Kurlander R, Chen Z, Kimelman ML, Remaley AT, Csako G, Thomas F, Eggerman TL, Patterson AP. Serum amyloid A binding to CLA-l (CD36 and LlMPII analogous-1) mediates serum amyloid A protein-induced activation of ERK1/2 and p38 mitogen-activated protein kinases. J Biol Chem. 2005;280:8031-40.
10. Benditt EP, Eriksen N. Amyloid II. Starch gel electrophoresis of some proteins extracted from amyloid. Arch Path. 1961;78:326-30.
11. Benditt EP, Eriksen N. Amyloid protein SAA is associated with high density lipoprotein from human serum. Proc Natl Acad Sci USA. 1977;74:4025-8.
12. Benditt EP, Eriksen N, Hanson RH. Amyloid protein SAA is an apoprotein of mouse plasma high density lipoprotein. Proc Natl Acad Sci USA. 1979;76:4092-6.
13. Benditt EP, Eriksen N, Hermonson MA, Ericsson LH. The major proteins of human and monkey amyloid substance: Common properties including unusual N-terminal amino acid sequences. FEBS ltrs. 1971;19:169-73.
14. Benditt EP, Meek RL. Expression of the third member of the serum amyloid A gene family in mouse adipocytes. J Exp Med. 1989;169:1841-6.
15. Betts JC, Cheshire JK, Akira S, Kishimoto T, Woo P. The role of NF-κB and NF-IL6 transactivating factors in the synergistic activation of human serum amyloid A gene expression by interleukin-1 and interleukin-6. J Biol Chem. 1993;268:25624-31.
16. Bing Z, Huang JH, Liao WS. NFkappa B interacts with serum amyloid A3 enhancer factor to synergistically activate mouse serum amyloid A3 gene transcription. J Biol Chem. 2000;275:31616-23.
17. Bozinovski S, Hutchinson A, Thompson M, MacGregor L, Black J, Giannakis E, Karlsson A-S, Silvestrini R, Smallwood D, Vlahos R, Irving LB, Anderson GP. Serum amyloid A is a biomarker of acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;177:269-78.
18. Bozinovski S, Uddin M, Vlahos R, Thompson M, McQualter JL, Merritt A-S, Wark PAB, Hutchinson A, Irving IB, Levy BD, Anderson GP. Serum amyloid A opposes lipoxin A4 to mediate glucocorticoid refractory lung inflammation in chronic obstructive pulmonary disease. Proc Natl Acad Sci USA. 2012;109:935-40.
19. Brasier AR, Ron D, Tate JE, Habener JF. A family of constitutive C/EBP-like DNA binding proteins attenuate the IL-1α induced, NF-κB mediated trans-activation of the angiotensinogen gene acute-phase response element. EMBO J. 1990;9:3933-44.
20. Brinckerhoff CE, Benoit MC, Culp WJ. Autoregulation of collagenase production by a protein synthesized and secreted by synovial fibroblasts: Cellular mechanism for control of collagen degradation. Proc Natl Acad Sci USA. 1985;82:1916-20.
21. Brinckerhoff CE, Gross RH, Nigase H, Sheldon L, Jackson RC, Harris ED Jr. Increased level of translatable collagenase messenger ribonucleic acid in rabbit synovial fibroblasts treated with phorbol myristate acetate or crystals of monosodium urate monohydrate. Biochem. 1982;21:2674-9.
22. Brinckerhoff CE, Mitchell TI. Autocrine control of collagenase synthesis by synovial fibroblasts. J Cell Phys. 1988;136:72-80.
23. 2-microglobulin-like proteins. Science. 1989;243:655-7.
24. Butler A, Whitehead AS. Mapping of the mouse serum amyloid A gene cluster by long-range polymerase chain reaction. Immunogenet. 1996;44:468-74.
25. Cabana VG, Feng N, Reardon CA, Lukens J, Webb NR, de Beer FC, Getz GS. Influence of apoA-1 and apoE on the formation of serum amyloidosis A-containing lipoproteins in vivo and in vitro. J Lipid Res. 2004;45:317-25.
26. Cabana VG, Siegel JN, Sabesin SM. Effects of the acute phase response on the concentration and density distribution of plasma lipids and apolipoproteins. J Lipid Res. 1989;30:39-49.
27. Cai L, deBeer MC, deBeer FC, van der Westhuysen DR. Serum amyloid A is a ligand for scavenger receptor class B type I and inhibits high density lipoprotein binding and selective lipid uptake. J Biol Chem. 2005;280:2954-61.
28. Carty CL, Heagerty P, Heckbert SR, Enquobahrie OS, Jarvik G, Davis S, Tracy RP, Reiner AP. Association of genetic variation in serum amylold-A with cardiovascular disease and interactions with IL6, IL1RN, IL1beta and TNF genes in the Cardiovascular Health Study. J Atheroscler Thromb. 2009;16:419-30.
29. Chae JJ, Aksentijevich I, Kastner DL. Advances in the understanding of familial Mediterranean fever and possibilities for targeted therapy. Br J Haematol. 2009;146:467-78.
30. Chen ES, Moller DR. Sarcoidosis - scientific progress and clinical challenges. Nat Rev Rheumatol. 2010;7:457-67.
31. Chen ES, Song Z, Willett MH, Heine S, Yung RC, Liu MC, Groshong SD, Zhang Y, Tuder RM, Moller DR. Serum amyloid A regulates granulomatous inflammation in sarcoidosis through Toll-like receptor-2. Am J Respir Crit Care Med. 2010;181:360-73.
32. Chen M, Zhou H, Cheng N, Qian F, Ye RD. Serum amyloid A1 isoforms display different efficacy at Toll-like receptor 2 and formyl peptide receptor 2. Immunobiol. 2014;219:916-23.
33. Cheng N, He R, Tian J, Ye PP, Ye RD. Cutting Edge: TLR2 is a functional receptor for acute-phase serum amyloid A. J Immunol. 2008;181:22-6.
34. Chiba T, Chany MY, Wang S, Wight TN, McMillen TS, Oram JF, Vaisar T, Heinecke JW, De Beer FC, De Beer MC, Chait A. Serum amyloid A facilitates the binding of high-density lipoprotein from mice injected with lipopolysaccharide to vascular proteoglycans. Arterioscler Thromb Vasc Biol. 2011;31:1326-32.
35. Choi HK, Hernán MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet. 2002;359:1173-7.
36. Claus S, Meinhardt K, Aumüller T, Puscalau-Girtu I, Linder J, Haupt C, Walther P, Syrovets T, Simmer T, Fndrich M. Cellular mechanism of fibril formation from serum amyloid a1 protein. EMBO Rep. 2017;18:1352-66.
37. Cocco E, Bellone S, El-Sahwi K, Cargnelutti M, Buza N, Tavassoli FA, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Serum Amyloid A - A novel biomarker for endometrial cancer. Cancer. 2010;116:843-51.
38. Cocco E, Bellone S, El-Sahwi K, Cargnelutti M, Casagrande F, Buza N, Tavassoli FA, Siegel ER, Visintin I, Ratner E, Silasi D-A, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Serum amyloid A (SAA): A novel biomarker for uterine serous papillary cancer. Br J Cancer. 2009;101:335-41.
39. Coetzee GA, Strachan AF, van der Westhuyzen DR, Hoppe HC, Jeenah MS, deBeer FC. Serum amyloid A-containing human high density lipoprotein 3. Density, size and apolipoprotein composition. J Biol Chem. 1986;261:9644-51.
40. Cohen AS, Calkins E. Electron microscopic observations on a fibrous component in amyloid of diverse origins. Nature. 1959;183:1202-3.
41. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GDO, Pepys MB, Gudnason V. C-reactive protein and other Circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387-97.
42. De Beer MC, Wroblewski JM, Noffsinger VP, Rateri DL, Howatt DA, Balakrishnan A, Ji A, Shridas P, Thompson JC, van der Westhuyzen DR, Tannock LR, Daugherty A, Webb NR, De Beer FC. Deficiency of endogenous acute phase serum amyloid A does not affect atherosclerotic lesions in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Bioi. 2014;34:255-61.
43. De Buck M, Gouwy M, Wang JM, Van Snick J, Proost P, Struyf S, Van Damme J. The cytokine-serum amyloid A-chemokine network. Cytokine Growth Factor Rev. 2016;30:55-69.
44. De Santo C, Arscott R, Booth S, Karydis I, Jones M, Asher R, Salio M, Middleton M, Cerundolo V. Invariant NKT cells modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum amyloid A. Nat Immunol. 2010;11:1039-46.
45. DeBeer MC, DeBeer FC, Gerardot CJ, Cecil DR, Webb NR, Goodson ML, Kindy MS. Structure of the mouse Saa4 gene and its linkage to the Serum Amyloid A Gene Family. Genomics. 1996;34:139-42.
46. deBeer MC, Webb NR, Wroblewski JM, Noffsinger VP, Rateri DL, Ji A, van der Westhuyzen DR, deBeer FC. Impact of serum amyloid A on high density lipoprotein composition and levels. J Lipid Res. 2010;51:3117-25.
47. Deguchi A, Tomita T, Omori T, Komatsu A, Ohto U, Takahashi S, Tanimura N, Akashi-Takamura S, Miyake K, Maru Y. Serum amyloid A3 binds MD-2 to activate p38 and NF-κB pathways in a MyD88-dependent manner. J Immunol. 2013;191:1856-64.
48. Delano MJ, Scumpia PO, Weinstein JS, Coco D, Nagaraj S, Kelly-Scumpia KM, O'Malley KA, Wynn JL, Amtonenko S, Al-Quran SZ, Swan R, Chung C-S, Atkinson MA, Ramphal R, Gabrilovich DI, Reeves WH, Ayala A, Phillips J, LaFace D, Heyworth PG, Clare-Salzer M, Moldawer LL. MyD88-dependent expansion of an immature GR-1+CDllb+ population induces T cell suppression and h2 polarization in sepsis. J Exp Med. 2007;204:1463-74.
49. Derebe MG, Ziatkov CM, Gattu S, Ruhn KA, Vaishnava S, Diehl GE, MacMillan JB, Williams NS, Hooper LV. Serum amyloid A is a retinol binding protein that transports retinol during bacterial infection, eLiFE; 2014. p. 03206.
50. Digre A, Nan J, Frank M, Li J-P. Heparin interactions with apoA1 and SAA in inflammation-associated HDL. Biochem Biophys Res Comm. 2016;474:309-14.
51. Djurec M, Graňa O, Lee A, Troulé K, Espinet E, Cabras L, Navas C, Blasco MT, Martin-Diaz L, Burdiel M, Li J, Liu Z, Vallespinós M, Sanchez-Bueno F, Sprick MR, Trumpp A, Sainz BJR, Al-Shahrour F, Rabadan R, Guerra C, Barbacid M. SAA3 is a key mediator of the protumorigenic properties of cancer-associated fibroblasts in pancreatic tumors. Proc Natl Acad Sci USA. 2018;115:E1147-56.
52. Donaldson GC, Seegmungal TA, Patel S, Bhowmik A, Wilkinson TM, Hurst JR, Maccallum PK, Wedzicha JA. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest. 2005;128:1995-2004.
53. Dufton N, Hannon R, Brancaleone V, Dalli J, Patel HB, Gray M, D'Acquisto F, Buckingham JC, Perretti M, Flower RJ. Anti-inflammatory role of the murine formyl-peptide receptor 2: Ligand-specific effects on leukocyte responses and experimental inflammation. J Immunol. 2010;184:2611-9.
54. Eanes ED, Glenner GG. X-ray diffraction studies on amyloid filaments. J Histochem Cytochem. 1968;16:673-7.
55. Eckhardt ERM, Witta J, Zhong J, Arsenescu R, Arsenescu V, Wang Y, Ghoshal S, deBeer MC, de Beer FC, de Villiers WJS. Intestinal epithelial serum amyloid A modulates bacterial growth in vitro and proinflammatory responses in mouse experimental colitis. BMC Gastroenterology. 2010;10:133.
56. Edbrooke MR, Burt DW, Cheshire JK, Woo P. Identification of cis-acting sequences responsible for phorbol ester induction of human serum amyloid A gene expression via a nuclear factor κB-like transcription factor. Mol Cell Biol. 1989;9:1908-16.
57. Edbrooke MR, Foldi J, Cheshire JK, Li F, Faulkes DJ, Woo P. Constitutive and NF-κB-like proteins in the regulation of the serum amyloid A gene by interleukin-1. Cytokine. 1991;3:380-8.
58. Edbrooke MR, Woo P. Regulation of human SAA gene expression by cytokines. In: Pepys M, editor. Acute Phase Proteins in the Acute Phase Response. London: Springer-Verlag; 1989. p. 21-7.
59. Edgell T, Martin-Roussety G, Barker G, Auteliano DJ, Allen D, Grant P, Rice GE. Phase II biomarker trial of a multimarker diagnostic for ovarian cancer. J Cancer Res Clin Oncol. 2010;136:1079-88.
60. Ein D, Kimura S, Glenner GG. An amyloid fibril protein of unknown origin: Partial amino acid sequence analysis. Biochem Biophys Res Commun. 1972a;46:498-500.
61. Ein D, Kimura S, Terry WD, Magnotta J, Glenner GG. Amino acid sequence of an amyloid fibril protein of unknown origin. J Bioi Chem. 1972b;247:5653-5.
62. Eisenberg D, Jucker M. The amyloid state of proteins in human diseases. Cell. 2012;148:1188-203.
63. El Kebir D, Jozsef L, Khreiss T, Pan W, Petasis NA, Serhan CN, Filep JG. Aspirin-triggered lipoxins override the apoptosis-delaying action of serum amyloid A in human neutrophils: A novel mechanism for resolution of inflammation. J ImmunoI. 2007;179:616-22.
64. 1 alleles. Amyloid. 1994;1:255-62.
65. Feingold KR, Grunfeld C. The acute phase response inhibits reverse cholesterol transport. J Lipid Res. 2010;51:682-4.
66. Findeisen P, Zapatka M, Peccerella T, Matzk H, Neumaier M, Schadendorf D, Ugure S. Serum Amyloid A as a prognostic marker in melanoma identified by proteomic profiling. J Clin Onc. 2009;27:2199-208.
67. Fiore S, Maddox JF, Perez HD, Serhan CN. Identification of a human cDNA encoding a functional high affinity lipoxin A4 receptor. J Exp Med. 1994;180:253-60.
68. Frame NM, Gursky O. Structure of serum amyloid A suggests a mechanism for selective lipoprotein binding and functions: SAA as a hub in macromolecular interaction networks. FEBS Lett. 2016;590:866-79.
69. Furlaneto CJ, Campa A. A novel function of serum amyloid A: a potent stimulus for the release of tumor necrosis factor-α, interleukin-lβ, and interleukin-8 by human blood neutrophil. Biochem Biophys Res Commun. 2000;268:405-8.
70. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448-54.
71. Gao JL, Murphy PM. Species and subtype variants of the N-formyl peptide chemotactic receptor reveal multiple important functional domains. J Biol Chem. 1993;268:25395-401.
72. Gardiner GE, O'Flaherty S, Casey PG, Weber A, McDonald TL, Cronin M, Hill C, Ross RP, Gahan CGM, Shanahan F. Evaluation of colostrum-derived human mammary-associated serum amyloid A3 (M-SAA3) protein and peptide derivatives for the prevention of enteric infection: in vitro and in murine models of intestinal disease. FEMS Immunol Med Microbiol. 2009;55:404-13.
73. Getz GA, Reardon CA. SAA, HDL biogenesis, and inflammation. J Lipid Res. 2008;49:269-70.
74. Getz GS, Krishack PA, Reardon CA. Serum amyloid A and atherosclerosis. Curr Opin Lipidol. 2016;27:531-5.
75. Ghanim H, Dhindsa S, Aljada A, Chaudhuri A, Viswanathan P, Dandona P. Low-dose rosiglitazone exerts an anti-inflammatory effect with an increase in adiponectin independently of free fatty acid fall and insulin sensitization in obese type 2 diabetics. J Clin Endocrinol Metab. 2006;91:3553-8.
76. Glenner GG, Page D, Isersky C, Harada M, Cuatrecasas P, Eanes ED, RA DL, Bladen HA, Keiser HR. Murine amyloid fibril protein: Isolation, purification and characterization. J Histochem Cytochem. 1971;19:16-28.
77. Gury-BenAri M, Thaiss CA, Serafini N, Winter DR, Giladi A, Lara-Astiaso D, Levy M, Salame TM, Weiner A, David E, Shapiro H, Dori-Bachhash M, Pevsner-Fischer M, Lorenzo-Vivas E, Keren-Shaul H, Paul F, Harmelin A, Ebery G, Itzkovitz S, Tanay A, DiSanto JP, Elinav E, Amit I. The spectrum and regulatory landscape of intestinal innate lymphoid cells are shaped by the microbiome. Cell. 2015;155:1231-46.
78. Gutfeld O, Prus D, Ackerman Z, Dishon S, Linke RP, Levin M, Urieli-Shoval S. Expression of Serum Amyloid A, in normal, dysplastic, and neoplastic human colonic mucosa: Implication for a role in colonic tumorigenesis. J Histochem Cytochem. 2006;54:63-73.
79. Hagihara K, Nishikawa T, Isobe T, Song J, Sugamata Y, Yoshizaki K. IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system. Biochem Biophys Res Commun. 2004;314:363-9.
80. Hagihara K, Nishikawa T, Sugamata Y, Song J, Isobe T, Taga T, Yoshizaki K. Essential role of STAT3 in cytokine-driven NF-κB-mediated serum amyloid A gene expression. Genes Cells. 2005;10:1051-63.
81. Hansen MT, Forst B, Cremers N, Quagliata L, Ambartsumian N, Grum-Schwensen B, Klinghofer J, Abdul-Al A, Herrmann P, Osterland M, Stein U, Nielsen GH, Scherer PE, Lukanidin E, Sleeman JP, Grigorian M. A link between inflammation and metastasis: serum amyloid A1 and A3 induce metastasis, and are targets of metastasis-inducing S100A4. Oncogene. 2015;34:424-35.
82. Hari-Dass R, Shah C, Meyer OJ, Raynes JG. Serum amyloid A protein binds to outer membrane protein A of gram-negative bacteria. J Biol Chem. 2005;280:18562-7.
83. Hass G Studies of amyloid II. The isolation of a polysaccharide from amyloid-bearing tissues1942
84. He R, Sang H, Ye RD. Serum amyloid A induces IL-8 secretion through a G protein-coupled receptor, FPRL1/LXA4R. Blood. 2003;101:1572-81.
85. He R, Shepard LW, Chen J, Pan ZK, Ye RD. Serum amyloid A is an endogenous ligand that differentially induces IL-12 and IL-23. J Immunol. 2006;177:4072-9.
86. He R, Zhou J, Hanson C, Chen J, Ye RD. The acute-phase protein serum amyloid A induces G-CSF expression and granulocytosis. J Leukoc Biol Suppl. 2007;44-45:abs 96.
87. Hiratsuka S, Watanabe A, Sakurai Y, Akashi-Takamura S, Ishibashi S, Miyake K, Shibuya M, Akira S, Aburatani H, Maru Y. The S100A8- serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nature Cell Biol. 2008;10:1349-55.
88. Hoffman JS, Benditt EP. Changes in high density lipoprotein content following endotoxin administration in the mouse. J Bioi Chem. 1982;257:10510-7.
89. Hosoai H, Webb NR, Glick JM, Tietge UJF, Purdom MS, de Beer FC, Rader DJ. Expression of serum amyloid A protein in the absence of the acute phase response does not reduce HDL cholesterol or apoA-levels in human apoA-1 transgenic mice. J Lip Res. 1999;40:648-53.
90. Hu W, Abe-Dohmae S, Tsujita M, Iwamoto N, Ogikubo O, Otsuka T, Kumon Y, Yokoyama S. Biogenesis of HDL by SAA is dependent on ABCA1 in the liver in vivo. J Lipid Res. 2008;49:386-93.
91. Huang JH, Liao WS. Synergistic induction of mouse serum amyloid A3 promoter by the inflammatory mediators IL-1 and IL-6. I Interferon Cytokine Res. 1999;12:1403-11.
92. Husby G, Natvig JB. A serum component related to nonimmunoglobulin amyloid protein AS, a possible precursor of the fibrils. J Clin Invest. 1974;53:1054-61.
93. Ibañez B, Fuster V. CANTOS A gigantic proof-of-concept trial. Cir Res. 2017;121:1320-2.
94. Ibrahim MI, Ramy AR, Abdelhamid AS, Ellaithy MI, Omar A, Harara RM, Fathy H, Abolouz AS. Maternal serum amyloid A level as a novel marker of primary unexplained recurrent early pregnancy loss. Int J Gynecol Obstet. 2017;136:298-303.
95. Ilay A, Schatten H, Ray BK. Activation of Sp1 and its functional co-operation with serum amyloid A-activating sequence binding factor in synoviocyte cells trigger synergistic action of interleukin-1 and interleukin-6 in serum amyloid A gene expression. J Biol Chem. 1999;274:4300-8.
96. Ivanov II, Atarashi K, Manel N, Brodie EL Shima T, Karaoz U, Wei D, Goldfarb KC, Santee CA, Lynch SV, Tanoue T, Imaoka A, Itoh K, Takeda K, Umcsaki Y, Honda K, Littman DR. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell. 2009;139:485-98.
97. Jayaraman S, Gantz DL, Haupt C, Gursky O. Serum amyloid A forms stable oligomers that disrupt vesicles at lysosomal pH and contribute to the pathogenesis of reactive amyloidosis. Proc Natl Acad Sci USA. 2017;114:E6507-15.
98. Jensen LE, Hiney MP, Shields DC, Uhlar CM, Lindsay AJ, Whitehead AS. Acute phase proteins in salmonids: evolutionary analyses and acute phase response. J ImmunoI. 1997;158:384-92.
99. Ji YR, Kim HJ, Bae KB, Lee S, Kim MO, Ryoo ZY. Hepatic serum amyloid A1 aggravates T Cell-mediated hepatitis by inducing chemokines via Toll-like receptor 2 in mice. J Biol Chem. 2015;290:12804-11.
100. Jiang S-L, Lozanski G, Samols D, Kushner I. Induction of human serum amyloid A in Hep3B cells by IL-6 and IL-1β involves both transcriptional and post-transcriptional mechanisms. J ImmunoI. 1995a;154:825-31.
101. Jiang S-L, Samols D, Rzewnicki D, Macintyre SS, Greber I, Sipe J, Kushner I. Kinetic modeling and mathematical analysis indicate that acute phase gene expression in Hep 3B cells is regulated by both transcriptional and posttranscriptional mechanisms. J Clin Inv. 1995b;95:1253-61.
102. Jousilahti P, Salomaa V, Rasi V, Vahtera E, Palosuo T. The association of C-reactive protein, serum amyloid a and fibrinogen with prevalent coronary heart disease - baseline findings of the PAIS project. Atherosclerosis. 2001;156:451-6.
103. Kennel SJ, Williams A, Stuckey A, Richey T, Wooliver C, Chazin W, Stern DA, Martin EB, Wall JS. The pattern recognition reagents RAGE VC1 and peptide p5 share common binding sites and exhibit specific reactivity with AA amyloid in mice. Amyloid. 2016;23:8-16.
104. Kerppola TK, Luk D, Curran T. Fos is a preferential target of glucocorticoid receptor inhibition of AP-1 activity in vitro. Mol Cell Biol. 1993;13:3782-2791.
105. Kim KD, Zhao J, Auh S, Yang X, Du P, Tang H, Fu Y-X. Adaptive immune cells temper initial innate responses. Nat Med. 2007;13:1248-52.
106. Kim MH, de Beer MC, Wroblewski JM, Webb NR, de Beer FC. SAA does not induce cytokine production in physiological conditions. Cytokine. 2013;61:506-12.
107. King VL, Thompson J, Tannock LR. Serum amyloid A in atherosclerosis. Curr Opin Lipidol. 2011;22:302-7.
108. Kinkley SM, Bagshaw WL, Tam SP, Kisilevsky R. The path of murine serum amyloid A through peritoneal macrophages. Amyloid. 2006;13:123-34.
109. Kisilevsky R, Manley PN. Acute-phase amyloid A: Perspectives on its physiological and pathological roles. Amyloid. 2012;19:5-14.
110. Kisilevsky R, Subrahmanyan L. Serum amyloid A changes high density lipoprotein's cellular affinity. Lab Inv. 1992;66:778-85.
111. Kisilevsky R, Tam SP. Macrophage cholesterol efflux and the active domains of serum amyloid A 2.1. J Lipid Res. 2003;44:2257-69.
112. Kluve-Beckerman B, Drumm ML, Benson MD. Nonexpression of the human serum amyloid A three (SAA3) gene. DNA Cell Biol. 1991;10:651-61.
113. Kluve-Beckerman B, Manaloor JJ, Liepnieks JJ. A pulse-chase study tracking the conversion of macroendocytosed serum amyloid A into extracellular amyloid. Arth Rheum. 2002;46:1905-13.
114. Kluve-Beckerman B, Naylor SL, Marshall A, Gardner JC, Shows TB, Benson MD. Localization of human SAA gene(s) to chromosome 11 and detection of DNA polymorphisms. Biochem Biophys Res Commun. 1986;137:1196-204.
115. Knebel FH, Uno M, Galatro TF, Bellé LP, Oba-Shinbjo SM, Marie SKN, Campa A. Serum amyloid A1 is upregulated in human glioblastoma. J Neurooncol. 2017;132:383-91.
116. Knee O, Gupta A, Curley A, Charnok-Jones DS, GCS S, Belteki G. The acute-phase protein SAA3 is present in the preterm human colostrum and breast milk. Arch. Dis. Child. Fetal Neonatal Ed. 2015;100:F369-71.
117. Knowles TPJ, Vendruscolo M, Dobson CM. The amyloid state and its association with protein misfolding diseases. Nat Rev Mol Cell Biol. 2014;15:384-96.
118. Knudsen PJ, Dinarello CA, Strom TB. Glucocorticoids inhibit transcriptional and post-transcriptional expression of interleukin 1 in U937 cells. J Immunol. 1987;139:4129-34.
119. Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M, Kishimoto T, Zinkernagel R, Bluethmann H, Kohler G. Impaired immune and acute-phase responses in Interleukin-6-deficient mice. Nature. 1994;368:339-42.
120. Koracevic A, Hammer A, Stadelmeyer E, Windischhofer W, Sundl R, Ray A, Schweighofer N, Friedl G, Windhager R, Sattler W, Malle W. Expression of serum amyloid A transcripts in human bone tissues, differentiated osteoblast-like stem cells and human osteosarcoma cell lines. J Cell Biochem. 2008;103:994-1004.
121. Kumon Y, Sipe JD, Brinckerhoff CE, Schreiber BM. Regulation of extrahepatic apolipoprotein Serum amyloid A gene expression by interleukin-1α alone. Scand J Immunol. 1997;46:284-91.
122. Kumon Y, Suehiro T, Faulkes DJ, Hosakawa T, Ikeda Y, Woo P, Sipe JD, Hashimoto K. Transcriptional regulation of serum amyloid Al gene expression in human aortic smooth muscle cells involves CCAAT/enhancer binding proteins (C/EBP) and is distinct from HepG2 cells. Scand J Immunol. 2002;56:504-11.
123. Kuroda T, Tanabe N, Hasegawa E, Wakamatsu A, Nozawa Y, Sato H, Nakatsue T, Wada Y, Ito Y, Imai N, Ueno M, Nakano M, Narita I. Significant association between renal function and area of amyloid deposition in kidney biopsy specimens in both AA amyloidosis associated with rheumatoid arthritis and AL amyloidosis. Amyloid. 2017;24:123-30.
124. Kushner I. The phenomenon of the acute phase response. Ann NY Acad Sci. 1982;39:39-48.
125. Lamkanfi M, Dixit VM. Mechanisms and function of inflammasomes. Cell. 2014;157:1013-22.
126. Lane T, Pinney JH, Gilbertson JA, Hutt DF, Rowczenio DM, Mahmood A, Sachchithanantham S, Fontana M, Youngstein T, Quarta CC, Wechalekar AD, Gillmore JD, Hawkins PN, Lachmann HJ. Changing epidemiology of AA amyloidosis: clinical observations over 25 years at a single national referral center. Amyloid. 2017;24:162-6.
127. Larson MA, Weber A, McDonald TL. Bovine serum amyloid A3 gene structure and promoter analysis: Induced transcriptional expression by bacterial components and the hormone prolactin. Gene. 2005b;380:104-10.
128. Larson MA, Weber A, Weber AT, McDonald TL. Differential expression and secretion of bovine serum amyloid A3 (SAA3) by mammary epithelial cells stimulated with prolactin or lipopolysaccharide. Vet Immunol lmmunopath. 2005a;107:255-4.
129. Larson MA, Wei SH, Weber A, Mack DR, McDonald TL. Human serum amyloid A3 peptide enhances intestinal MUC3 expression and inhibits EPEC adherence. Biochem Biophys Res Comm. 2003b;300:531-40.
130. Larson MA, Wei SH, Weber A, Weber AT, McDonald TL. Induction of human mammary-associated serum amyloid A3 expression by prolactin or lipopolysaccharide. Biochem Biophys Res Comm. 2003a;301:1030-7.
131. Lavie G, Zucker-Franklin D, Franklin EC. Degradation of serum amyloid A protein by surface-associated enzymes of human blood monocytes. J Exp Med. 1978;148:1020-31.
132. Lee HY, Kim MK, Park KS, Bae YH, Yun J, Park JL, Kwak JY, Bae YS. Serum amyloid A stimulates matrix-metalloproteinase-9 upregulation via formyl peptide receptor like-1 mediated signaling in human monocytic cells. Biochem Biophys Res Commun. 2005;330:989-98.
133. Levin M, Franklin EC, Frangione B, Pras M. The amino acid sequence of a major nonimmunoglobulin component of some amyloid fibrils. J Clin Inv. 1972;51:2773-6.
134. Li J-P, Galvis MLE, Gong F, Zhang X, Zcharia E, Metzger S, Vlodavsky I, Kisilevsky R, Lindahl U. In vivo fragmentation of heparin sulfate by heparanase overexpression renders mice resistant to amyloid protein A amyloidosis. Proc Natl Acad Sci USA. 2005;102:6473-7.
135. Li W, Zhu S, Li J, D'Amore J, D'Angelo J, Yang H, Wang P, Tracey KJ, Wang H. Serum amyloid A stimulates PKR expression and HMGB1 release possibly through TLR4/RAGE receptors. Mol Med. 2015;21:515-25.
136. Lin Y, Rajala MW, Berger JP, Moller DE, Barzsilai N, Scherer OE. Hyperglycemia-induced production of acute phase reactants in adipose tissue. J Biol Chem. 2001;276:42077-83.
137. Linke RP, Meinel A, Chalcroft JP, Urieli-Shoval S. Serum amyloid A (SAA) treatment enhances the recovery of aggravated polymicrobial sepsis in mice, whereas blocking SAA's invariant peptide results in early death. Amyloid. 2017;24(S1):149-50.
138. Linke RP, Sipe JD, Pollock PS, Ignaczak TF, Glenner GG. Isolation of a low-molecular-weight serum component antigenically related to an amyloid fibril protein of unknown origin. Proc Natl Acad Sci USA. 1975;72:1473-6.
139. Lowell CA, Potter DA, Stearman RS, Morrow JF. Structure of the murine serum amyloid A gene family: Gene conversion. J Biol Chem. 1986a;261:8442-52.
140. Lowell CA, Stearman RS, Morrow JF. Transcriptional regulation of serum amyloid A gene expression. J Biol Chem. 1986b;261:8453-61.
141. Lu J, Yu Y, Zhu I, Cheng Y, Sun PD. Structural mechanism of serum amyloid A-mediated inflammatory amyloidosis. Proc Natl Acad Sci USA. 2014;111:5189-94.
142. Luchtefeld M, Schunkert H, Stoll M, Selle T, Lorier R, Grote K, Sagebiel C, Jagavelu K, Tietge UJF, Assmus U, Streetz K, Hengstenberg C, Fischer M, Mayer B, Maresso K, El Mokhtari NE, Schreiber S, Muller W, Bavendiek U, Grothusen C, Drexler H, Trautwein C, Broeckel U, Schieffer B. Signal transducer of inflammation gp130 modulates atherosclerosis in mice and man. J Exp Med. 2007;204:1935-44.
143. Lundmark K, Westermark GT, Olsen A, Westermark P. Protein fibrils in nature can enhance amyloid protein A amyloidosis in mice: cross-seeding as a disease mechanism. Proc Natl Acad Sci USA. 2005;102:6098-102.
144. Mack DR, McDonald TL, Larson MA, Wei S, Weber A. The conserved TFLK motif of mammary-associated serum amyloid A3 is responsible for up-regulation of intestinal MUC3 mucin expression In Vitro. Ped Res. 2003;53:137-14.
145. Macleod CM, Avery OT. The occurrence during acute infections of a protein not normally present in the blood. J Exp Med. 1941;73:183-90.
146. Man SF, Connett JE, Anthonisen NR, Wise RA, Tashkin DP, Sin DD. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax. 2006;61:849-53.
147. Mao K, Baptista AP, Tamaoutounour S, Zhuang L, Bouladoux N, Martins AJ, Huang Y, Gerner MY, Belkaid Y, Germain RN. Innate and adaptive lymphocytes sequentially shape the gut microbiota and lipid metabolism. Nature. 2018;554:255-9.
148. Marsche G, Frank S, Raynes JG, Kozarsky KF, Sattler W, Malle E. The lipidation status of acute-phase protein serum amyloid A determines cholesterol mobilization via scavenger receptor class B, type 1. Biochem J. 2007;402:117-24.
149. Marx N, Froehlich J, Siam L, Ittner J, Wierse G, Schmidt A, Scharnagl H, Hombach V, Koenig W. Antidiabetic PPARy-Activator Rosiglitazone reduces MMP-9 serum levels in Type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol. 2003;23:283-8.
150. Marzi C, Albrecht E, Hysi PG, Lagou V, Waldenberger M, Tonjes A, Prokopenko J, Heim K, Blackburn H, Ried JS, Kleber ME, Mangino M, Thorand B, Peters A, Hammond CJ, Graliert HO, Boehm B, Kovacs P, Geistlinger L, Prokisch H, Winkelmann BR, Spector TO, Wichmann H-E, Stumvoll M, Soranzo N, Marz W, Koenig W, Illig T, Gieger C. Genome-wide association study identifies two novel regions at 11p15.5-p13 and 1p31 with major impact on acute-phase serum amyloid A. PLOS Genet. 2010;6:1-8.
151. McDonald TL, Larson MA, Mack DR, Weber A. Elevated extrahepatic expression and secretion of mammary-associated serum amyloid A3 (M-SAA3) into colostrum. Vet Immunol lmmunopath. 2001;83:203-11.
152. McDonald TL, Weber A, Smith JW. A monoclonal antibody sandwich immunoassay for serum amyloid A (SAA) protein. J Immunol Meth. 1991;144:149-55.
153. McGillicuddy FC, de la Llera MM, Hinkle CC, Joshi MR, Chiquone EH, Billheimer JT, Rothblat GH, Reilly MP. Inflammation impairs reverse cholesterol transport in vivo. Circ. 2009;119:1135-45.
154. McGlennen RC, Burke BA, Dehner LP. Systemic amyloidosis complicating cystic fibrosis: A retrospective pathologic study. Arch Pathol Lab Med. 1986;110:879-84.
155. Meek RL, Hoffman JS, Benditt EP. Amyloidogenesis - One serum amyloid A isotype is selectively removed from the circulation. J Exp Med. 1986;163:499-510.
156. Meek RL, Urieli-Shoval S, Benditt EP. Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: implications for serum amyloid A function. Proc Natl Acad Sci USA. 1994;91:3186-90.
157. Meeker AK, Sack GH Jr. A fusion protein between Serum Amyloid A and Staphylococcal Nuclease - Synthesis, purification, and structural studies. Proteins. 1998;30:381-7.
158. Migita K, Kawabe Y, Tominaga M, Riguchi TO, Aoyagi T, Eguchi K. Serum amyloid A protein induces production of matrix metalloproteinases by human synovial fibroblasts. Lab Invest. 1998;78:535-9.
159. Mitchell TI, Coon CI, Brinckerhoff CE. Serum amyloid A (SAA3) produced by rabbit synovial fibroblasts treated with phorbol esters or Interleukin 1 induces synthesis of collagenase and is neutralized with specific antiserum. J Clin Invest. 1991;87:1177-85.
160. Mitchell TI, Jeffrey JJ, Palmiter RD, Brinckerhoff CE. The acute phase reactant serum amyloid A (SAA3) is a novel substrate for degradation by the metalloproteinases collagenase and stromolysin. Biochim Biophys Acta. 1993;1156:245-54.
161. Mithal LB, Palac HL, Yogev R, Ernst LM, Mestan KK. Cord blood acute phase reactants predict early onset neonatal sepsis in preterm infants. PLOS one. 2017; https://doi.org/10.1371/journal.pone.0168677.
162. Mori M, Tiang G, Higuchi K. AA amyloidosis-resistant CE/J mice have Saal and Saa2 genes that encode an identical SAA isoform. Amyloid. 2014;21:1-8.
163. Moriguchi M, Kaneko H, Terai C, Koseki Y, Kajiyama H, Inada S, Kitamura Y, Kamatani N. Relative transcriptional activities of SAA1 promoters polymorphic at position -13 (T/C): Potential association between increased transcription and amyloidosis. Amyloid. 2005;12:26-32.
164. Morrow JF, Stearman RS, Peltzman CG, Potter DA. Induction of hepatic synthesis of serum amyloid A protein and actin. Proc Natl Acad Sci USA. 1981;78:4718-22.
165. Moshkovskii SA, Serebryakova MV, Kuteykin-Teplyakov KB, Tikhonova OV, Goufman EI, Zgoda VG, Taranets IN, Makarov OV, Archakov AI. Ovarian cancer marker of 11.7 kDa detected by proteomics is a serum amyloid A1. Proteomics. 2005;5:3790-7.
166. Mullan RN, Bresnihan B, Golden-Mason L, Markham T, O'Hara R, FitzGerald O, Veale DJ, Fearon U. Acute-phase serum amyloid A stimulation of angiogenesis, leukocyte recruitment, and matrix degradation in rheumatoid arthritis through an NF-κB-dependent signal transduction pathway. Arthritis Rheum. 2006;54:105-14.
167. Murakami M, Hibi M, Nakagawa N, Nakagawa T, Yasukawa K, Yamanishi K, Taga T, Kishimoto T. IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science. 1993;260:1808-10.
168. Nacu S, Yuan W, Kan Z, Bhatt D, Rivers CS, Stinson J, Peters BA, Modrusan Z, Jung K, Seshagiri S, Wu TD. Deep RNA sequencing analysis of readthrough gene fusions in human prostate adenocarcinoma and reference samples. BMC Med Genom. 2011;4:11.
169. Nagy E, Maquat LE. A rule for termination-codon position within intron-containing genes: when nonsense affects RNA abundance. TIBS. 1998;23:198-9.
170. Newton K, Dixit VM. Signaling in innate immunity and inflammation. Cold Spring Harb Perspec Biol. 2012;4:1-19.
171. Noborn F, Ancsin JB, Ubhayasekera W, Kisilevsky R, Li J-P. Heparan sulfate dissociates serum amyloid A (SAA) from acute-phase lipoprotein, promoting SAA aggregation. J Biol Chem. 2012;287:25669-77.
172. O'Brien KD, Chait A. Serum amyloid A: The "Other" inflammatory protein. Curr Atherosclerosis Rep. 2006;8:62-8.
173. O'Brien KD, McDonald TO, Kunjathoor V, Eng KL, Knopp EA, Lewis K, Lopez R, Kirk EA, Chait A, Wight TN, deBeer FC, LeBoeuf RC. Serum amyloid A and lipoprotein retention in murine models of atherosclerosis. Arterioscler Thromb Vasc Bioi. 2005;25:785-90.
174. O'Hara R, Murphy EP, Whitehead AS, FitzGerald O, Bresnihan B. Local expression of the serum amyloid A and formyl peptide receptor-like 1 genes in synovial tissue is associated with matrix metalloproteinase production in patients with inflammatory arthritis. Arthritis Rheum. 2004;50:1788-99.
175. Paret C, Schon Z, Szponar A, Kovacs G. Inflammatory protein serum amyloid A1 marks a subset of conventional renal cell carcinomas with fatal outcome. Eur Urol. 2010;57:859-66.
176. Patel H, Bramall J, Waters H, DeBeer MC, Woo P. Expression of recombinant human serum amyloid A in mammalian cells and demonstration of the region necessary for high-density lipoprotein binding and amyloid fibril formation by site-directed mutagenesis. Biochem J. 1996;318:1041-9.
177. Patel H, Fellowes R, Coade S, Woo P. Human serum amyloid A has cytokine-like properties. Scand J ImmunoI. 1998;48:410-8.
178. Pauling L, Corey RB. Configurations of polypeptide chains with favored orientation around single bonds: Two new pleated sheets. Proc Natl Acad Sci USA. 1951;37:729-40.
179. Pedicord VA, Mucida D. "A sledgehammer breaks glass but forges steel": Bacteria adhesion shapes gut immunity. Cell. 2015;153:273-4.
180. Pepys MB. Pathogenesis, diagnosis and treatment of systemic amyloidosis. Phil Trans R Soc Lond B. 2001;356:203-11.
181. Poltorak A, He X, Smirnova I, Liu M-Y, van Huffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B, Beutler B. Defective LPS signaling in C3H/Hej and C57BL/10ScCr mice: mutations in the Tlr4 gene. Science. 1998;282:2085-8.
182. Prelli F, Pras M, Frangione B. Degradation and deposition of amyloid AA fibrils are tissue specific. Biochem. 1987;26:8251-6.
183. Qian H, Zhao X, Cao P, Lei J, Van N, Gong X. Structure of the human lipid exporter ABCA1. Cell. 2017;169:1228-39.
184. Quinton U, Blahna MT, Jones MR, Allen E, Ferrari JD, Hilliard KL, Zhang X, Sabharwal V, Algal H, Akira S, Schmid RM, Pelton SI, Spira A, Mizgerd JP. Hepatocyte-specific mutation of both NF-κB RelA and STAT3 abrogates the acute phase response in mice. J Clin Inv. 2012;122:1758-63.
185. Quinton U, Jones MR, Robson BE, Mizgerd JP. Mechanisms of the hepatic acute-phase response during bacterial pneumonia. Infect Immun. 2009;77:2417-26.
186. Ranlov P. The adoptive transfer of experimental mouse amyloidosis by intravenous injections of spleen cell extracts from casein treated syngenic donor mice. Acta Path Microbiol Scand. 1967;70:321-35.
187. Ray A, Bal BS, Ray BK. Transcriptional induction of matrix metalloproteinase-9 in the chondrocyte and synoviocyte cells is regulated via a novel mechanism: evidence for functional cooperation between serum amyloid A-activating factor-1 and AP-l. J ImmunoI. 2005;175:4039-48.
188. Ray A, Kumar D, Ray P, Ray BK. Transcriptional activity of serum amyloid A-activating factor-1 is regulated by distinct functional modules. J Biol Chem. 2004a;279:54637-46.
189. Ray A, Kumar D, Shakya A, Brown CR, Cook JL, Ray BK. Serum amyloid A-activating factor (SAF-1) transgenic mice are prone to develop a severe form of inflammation-induced arthritis. J Immunol. 2004b;173:4684-91.
190. Ray A, Ray BK. A novel cis-acting element is essential for cytokine-mediated transcriptional induction of the serum amyloid A gene in nonhepatic cells. Mol Cell Biol. 1996;16:1584-94.
191. Ray A, Shakya A, Kumar D, Benson MD, Ray BK. Inflammation-responsive transcription factor SAF-1 activity is linked to the development of amyloid A amyloidosis. J Immunol. 2006;177:2601-9.
192. Ray A, Shang DH, Siegel MD, Ray P. Regulation of interleukin-6 gene expression by steroids. Ann N Y Acad Sci. 1995;762:79-87.
193. Reigstad CS, Lundén GO, Felin J, Bockhed F. Regulation of Serum Amyloid A3 (SAA3) in mouse colonic epithelium and adipose tissue by the intestinal microbiota. PLOS one. 2009; https://doi.org/10.1371/journal.pone.0005842.
194. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E. C-reactive protein levels and outcomes after statin therapy. New Engl J Med. 2005;351:20-8.
195. Ridker PM, Danielson E, FAH F, Genest J, AMJr G, JJP K, Koenig W, Libby P, Lorenzatti AJ, JG MF, Bordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, for the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New Engl J Med. 2008;359:2195-207.
196. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau F, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ, for the CANTOS trial group. Antiinflammatory therapy with Canakinumab for atherosclerotic disease. New Engl J Med. 2017;377:1119-31.
197. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-43.
198. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557-65.
199. Riek R, Eisenberg DS. The activities of amyloids from a structural perspective. Nature. 2016;539:227-35.
200. Rienhoff HY Jr, Groudine M. Regulation of Amyloid A gene expression in cultured cells. Mol Cell BioI. 1988;8:3710-6.
201. Rosenthal CJ, Franklin EC, Frangione B, Greenspan J. Isolation and partial characterization of SAA-an amyloid-related protein from human serum. J ImmunoI. 1976;116:1415-8.
202. Rosenthal CJ, Sullivan LM. Serum amyloid A to monitor cancer dissemination. Ann Int Med. 1979;91:383-90.
203. Ross R. Atherosclerosis: a defense mechanism gone awry. Am J Path. 1993;143:987-1002.
204. Ross R. Atherosclerosis - An inflammatory disease. N Engl J Med. 1999;340:115-26.
205. Rust S, Rosier M, Funke H, Real J, Amoura Z, Piette J-C, Deleuze J-F, Brewer HB, Duverger N, Denèfle P, Assmann G. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet. 1999;22:352-5.
206. Rocken C, Kientsch-Engel SM, Stix B, Stubenrach K, Weigle B, Buhling F, Schwan M, Saeger W. Advanced glycation end products and receptor for advanced glycation end products in AA amyloidosis. Amer J Path. 2003;162:1213-20.
207. Rocken C, Menard R, Bühling F, Vockler S, Raynes J, Stix B, Krüger S, Roessner A, Khne T. Proteolysis of serum amyloid A and AA amyloid proteins by cysteine proteases: cathepsin B generates AA amyloid proteins and cathepsin L may prevent their formation. Ann Rheum Dis. 2005;64:808-15.
208. Sack GH Jr. Molecular cloning of human genes for serum amyloid A. Gene. 1983;21:19-24.
209. Sack GH Jr, Talbot CC Jr. The human serum amyloid A (SAA)-encoding gene GSAA1: nucleotide sequence and possible autocrine collagenase-inducer function. Gene. 1989;84:509-15.
210. Sack GH Jr, Talbot CC Jr, Seuanez H, O'Brien SJ. Molecular analysis of the human serum amyloid A (SAA) gene family. Scand J Immunol. 1989;29:113-9.
211. Sack GH Jr, Zachara N, Rosenblum N, Talbot CC Jr, Kreimer S, Cole R, TJ MD. Serum amyloid A1 (SAA1) protein in human colostrum. FEBS Open Bio. 2018;8:1-7.
212. Sack GH Jr, Zink MC. Serum amyloid A (SAA) gene expression in synovial cells in retroviral arthritis. Am J Path. 1992;141:525-9.
213. Sander LE, Sackett SD, Dierssen Y, Beraza N, Linke RP, Müller M, Blander JM, Tacke F, Trautwein C. Hepatic acute-phase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function. J Exp Med. 2010;207:1453-64.
214. Sandri S, Borbely AU, Fernandes I, deOliveira EM, Knebel FH, Ruano R, Zugaib M, Filippin-Monteiro F, Bevilaqua E, Campa A. Serum Amyloid A in the Placenta and its Role in Trophoblast Invasion. PLOSone. 2014; https://doi.org/10.1371/journal.pone.0090881.
215. Sandri S, Rodriguez D, Gomes E, Monteiro HP, Russo M, Campa A. Is serum amyloid A an endogenous TLR4 agonist? J Leukoc Bioi. 2008;83:1174-80.
216. Sano T, Huang W, Hall JA, Yang Y, Chen A, Gavzy SJ, Lee J-Y, Ziel JW, Miraldi ER, Domingos AI, Bonneau R, Littman DR. An IL-23R/IL-22 circuit regulates epithelial serum amyloid A to promote local effector Th17 responses. Cell. 2015;163:381-93.
217. Sawmynaden P, Perretti M. Glucocortocoid upregulation of the annexin-A1 receptor in leukocytes. Biochem Biophys Res Commun. 2006;349:1351-5.
218. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr. Role of transcriptional activation of IκBα in mediation of immunosuppression by glucocorticoids. Science. 1995b;270:283-6.
219. Scheinman RI, Gualberto A, Jewell CM, Cidlowski JA, Baldwin AS Jr. Characterization of mechanisms involved in transrepression of NF-kappaB by activated glucocorticoid receptor. Mol Cell Biol. 1995a;15:943-53.
220. Shah C, Hari-Dass R, Raynes JG. Serum amyloid A is an innate immune opsonin for Gram-negative bacteria. Blood. 2006;108:1751-7.
221. Sipe J. Revised nomenclature for serum amyloid A (SAA). Nomenclature Committee of the International Society of Amyloidosis. Part 1. Amyloid. 1999;6:67-70.
222. Song Z, Marsilli L, Greenlee BM, Chen ES, Silver RF, Askin FB, Teirstein AS, Zhang Y, Cotter RJ, Moller DR. Mycobacterial catalase-peroxidase is a tissue antigen and target of the adaptive immune response in systemic sarcoidosis. J Exp Med. 2005;201:755-67.
223. Spodzieja M, Rafalik M, Szymańska A, Kolodziejczyk AS, Czaplewska P. Interaction of serum amyloid A with human cystatin C - assessment of amino acid residues crucial for hCC-SAA formation (part II). J Mol Recognit. 2013;26:415-25.
224. Srinivasan S, Patke S, Wang Y, Ye Z, Litt J, Srivastava SK, Lopez MM, Kurouski D, Lednev IK, Kane RS, Colon W. Pathogenic Serum Amyloid A 1.1 shows a long oligomer-rich fibrillation lag phase contrary to the highly amyloidogenic non-pathogenic SAA2.2. J Biol Chem. 2013;288:2744-55.
225. Steel DM, Roger JT, DeBeer MC, DeBeer FC, Whitehead AS. Biosynthesis of human acute-phase serum amyloid A protein (A-SAA) in vitro: the roles or mRNA accumulation, poly (A) tail shortening and translational efficiency. Biochem J. 1993b;291:701-7.
226. Steel DM, Sellar GC, Uhlar CM, Simon S, deBeer FC, Whitehead AS. A constitutively expressed serum amyloid A protein gene is closely linked to, and shares structural similarities with, an acute phase serum amyloid A protein gene. Genomics. 1993a;16:447-54.
227. Stevens JF. Hypothetical structure of human serum amyloid A protein. Amyloid. 2004;11:71-80.
228. Stix B, Kähne T, Sletten K, Raynes J, Roessner A, Rocken C. Proteolysis of AA amyloid fibril proteins by matrix metalioproteinases-1,- 2, and -3. Am J PathoI. 2001;159:561-70.
229. Stonik JS, Remaley AT, Demosky SJ, Neufeld EB, Bocharov A, Brewer HB. Serum amyloid A promotes ABCA1-dependent and ABCA1- independent lipid efflux from cells. Biochem Biophys Res Comm. 2004;321:936-41.
230. Strissel KJ, Girard MT, West-Mays J-A, Rinehart WB, Cook JR, Brinckerhoff CE, Fini ME. Role of serum amyloid A as an intermediate in the IL-1 and PMA-stimulated signaling pathways regulating expression of rabbit fibroblast collagenase. Exp Cell Res. 1997;237:275-87.
231. Su SB, Gong W, Gao J-L, Shen W, Murphy PM, Oppenheim JJ, Wang JM. A seven-transmembrane, G protein-coupled receptor, FPRLl, mediates the chemotactic activity of serum amyloid A for human phagocytic cells. J Exp Med. 1999;189:395-402.
232. Suissa S, Bernatsky S, Hudson M. Antirheumatic drug use and the risk of acute myocardial infarction. Arth Rheum. 2006;55:531-6.
233. 2, Group IIA is a novel serum amyloid A target gene. J Biol Chem. 2010;285:565-75.
234. Sun L, Ye RD. Serum amyloid AI: Structure, function and gene polymorphism. Gene. 2016;583:48-57.
235. Sun L, Zhou H, Zhu Z, Yan Q, Wang L, Liang Q, Ye RD. Ex Vivo and In Vitro effect of serum amyloid A in the induction of macrophage M2 markers and efferocytosis of apoptotic neutrophils. J Immunol. 2015;194:4891-900.
236. Sunde M, Serpell LC, Bartlam M, Fraser PE, Pepys MB, Blake CCF. Common core structure of amyloid fibrils by synchrotron X-ray diffraction. J Mol Bioi. 1997;273:729-39.
237. Sung H-J, Ahn J-M, Yoon Y-H, Rhim ZT-Y, Park C-S, Park J-Y, Lee S-Y, Kim E-W, Cho J-Y. Identification and validation of SAA as a potential lung cancer biomarker and its involvement in metastatic pathogenesis of lung cancer. J Proteome Res. 2011;10:1383-95.
238. Takase H, Tanaka M, Miyagawa S, Yamada T, Mukai T. Effect of amino acid variations in the central region of human serum amyloid A on the amyloidogenic properties. Biochem Biophys Res Comm. 2014;444:92-7.
239. Takase H, Tanaka M, Yamamoto A, Watanabe S, Takahashi S, Nadanaka S, Kitagawa H, Yamada T, Mukai T. Structural requirements of glycosaminoglycans for facilitating amyloid fibril formation of human serum amyloid A. Amyloid. 2016;23(2):67-75.
240. Tam SP, Flexman A, Hulme J, Kisilevsky R. Promoting export of macrophage cholesterol: the physiological role of a major acute phase protein, serum amyloid A 2.1. J Lipid Res. 2002;43:1410-20.
241. Taylor BA, Rowe L. Genes for serum amyloid A proteins map to chromosome 7 in the mouse. Mol Gen Genet. 1984;195:491-9.
242. Thompson JC, Jayne C, Thompson J, Wilson PG, Yoder MH, Webb N, Tannock LR. A brief elevation of serum amyloid A is sufficient to increase atherosclerosis. J Lipid Res. 2015;56:286-93.
243. Thorn CF, Whitehead AS. Differential glucocorticoid enhancement of the cytokine-driven transcriptional activation of the human acute phase serum amyloid genes, SAA1 and SAA2. J ImmunoI. 2002;169:399-405.
244. Thorn CF, Whitehead AS. Tissue-specific regulation of the human acute-phase serum amyloid A genes, SAA1 and SAA2, by glucocorticoids in hepatic and epithelial cells. Eur J Immunol. 2003;33:2630-9.
245. Tillett WS, Francis T Jr. Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus. J Exp Med. 1930;52:561-71.
246. Tolson J, Bogumil R, Brunst E, Beck H, Elsner R, Humeny A, Kratzin H, Deeg M, Kuczyk M, Mueller GA, Mueller CA, Flad T. Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients. Lab Invest. 2004;84:845-56.
247. Tomita T, Ieguchi K, Sawamura T, Maru Y. Human serum amyloid A3 (SAA3) protein, expressed as a fusion protein with SAA2, binds the oxidized low density lipoprotein receptor. PLOS one. 2015; https://doi.org/10.1371/journal.pone.0118835.
248. Tucker PC, Sack GH Jr. Expression of serum amyloid A (SAA) genes in mouse brain - unprecedented response to inflammatory mediators. FASEB J. 2001;15:2241-6.
249. Tükel C, Wilson RP, Nishimori JH, Pezeshki M, Chromy BA, Bumler AJ. Responses to amyloids of microbial and host origin are mediated through Toll-like receptor 2. Cell Host and Microbe. 2009;6:45-53.
250. Turnell W, Sarra R, Glover ID, Baum JO, Caspi O, Baltz ML, Pepys MB. Secondary structure prediction of human SAA1. Presumptive identification of calcium and lipid binding sites. Mol Biol Med. 1986;3:387-407.
251. Uhlar CM, Burgess CJ, Sharp PM, Whitehead AS. Evolution of the serum amyloid A (SAA) protein superfamily. Genomics. 1994;19:228-35.
252. Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem. 1999a;265:S01-523.
253. Uhlar CM, Whitehead AS. The kinetics and magnitude of the synergistic activation of the serum amyloid A promoter by IL-1β and IL-6 is determined by the order of cytokine addition. Scand J ImmunoI. 1999b;49:399-404.
254. Urieli-Shoval S, Cohen P, Eisenberg S, Matzner Y. Widespread expression of serum amyloid A in histologically normal human tissues: Predominant localization to the epithelium. J Histochem Cytochem. 1998;46:1377-84.
255. Urieli-Shoval S, Finci-Yeheskel Z, Dishon S, Galinsky D, Linke RP, Ariel I, Levin M, Ben-Shachar I, Prus D. Expression of Serum Amyloid A in human ovarian epithelial tumors: Implication for a role in ovarian tumorigenesis. J Histochem Cytochem. 2010;58:1015-23.
256. Vallon R, Freuler F, Desta-Tesdu N, Robeva A, Dawson J, Wenner P, Engelhardt P, Boes L, Schnyder J, Tschopp C, Urfer R, Baumann G. Serum amyloid A (apoSAA) expression is up-regulated in rheumatoid arthritis and induces transcription of matrix metalloproteinases. J Immunol. 2001;166:2801-7.
257. van der Hilst JC, Yamada T, Op den Camp TJ, van der Meer JW, Drenth JP, Simon A. Increased susceptibility of serum amyloid A 1.1 to degradation by MMP-1: potential explanation for higher risk of type AA amyloidosis. Rheumatol (Oxford). 2008;47:1651-4.
258. van der Westhuyzen DR, Cai L, deBeer MC, de Beer FC. Serum amyloid A promotes cholesterol efflux mediated by scavenger receptor B-1. J Biol Chem. 2005;280:35890-5.
259. van der Westhuyzen DR, Coetzee GA, deBeer FC. Serum amyloid A protein in plasma: Characteristics of acute phase HDL. In: Marrink J, van Rijswijk MH, editors. Amyloidosis. Dordrecht: Martinus Nijhoff; 1986. p. 115-25.
260. van Gerven N, Klein RD, Hultgren SJ, Remaut H. Bacterial amyloid formation:Structural insights into curli biogenesis. Trends in Microbiol. 2009;23:693-706.
261. Veglia F, Perego M, Gabrilovich D. Myeloid-derived suppressor cells coming of age. Nat Immunol. 2018;19:108-19.
262. Wang L, Lashuel HA, Colon W. From hexamer to amyloid: Marginal stability of apolipoprotein SAA2.2 leads to in vitro fibril formation at physiological temperature. Amyloid. 2005;12:139-48.
263. Wang L, Lashuel HA, Walz T, Colon W. Murine apolipoprotein serum amyloid A in solution forms a hexamer containing a central channel. Proc Natl Acad Sci USA. 2002;99:15947-52.
264. Wang Y, Srinivasan S, Ye Z, Aguilera J, Lopez MM, Colon W. Serum amyloid A 2.2 refolds into a octameric oligomer that slowly converts to a more stable hexamer. Biochem Biophys Res Commun. 2011;407:725-9.
265. Weber A, Weber AT, McDonald TL, Larson MA. Staphylococcus aureus lipotechoic acid induces differential expression of bovine serum amyloid A3 (SAA3) by mammary epithelial cells: Implications for early diagnosis of mastitis. Vet Immunol lmmunopath. 2005;109:79-83.
266. Westermark GT, Sletten K, Westermark P. Massive vascular AA-Amyloidosis: A histologically and biochemically distinctive subtype of reactive systemic amyloidosis. Scand J Immunol. 1989;30:605-13.
267. Westermark GT, Westermark P. Prion-like aggregates: infectious agents in human disease. Trends Mol Med. 2010;16:501-7.
268. Westermark P. Aspects on human amyloid forms and their fibril polypeptides. FEBS J. 2005;272:5942-9.
269. Wilson PG, Thompson JC, Webb NR, deBeer FC, King VL, Tannock LR. Serum Amyloid A, but not C-reactive protein, stimulates vascular proteoglycan synthesis in a pro-atherogenic manner. Am J Pathol. 2008;173:1902-20.
270. Woo P, Sipe J, Dinarello CA, Colten HR. Structure of a human serum amyloid A gene and modulation of its expression in transfected L cells. J Biol Chem. 1987;262:15790-5.
271. Wood SL, Rogers M, Cairns DA, Paul A, Thompson D, Vasudev NS, Selby PJ, Banks RE. Association of serum amyloid A protein and peptide fragments with prognosis in renal cancer. Br J Cancer. 2010;103:101-11.
272. Wroblewski JM, Jahangiri A, Ji A, deBeer FC, van der Westhuyzen DR, Webb NR. Nascent HDL formation by hepatocytes is reduced by the concerted action of serum amyloid A and endothelial lipase. J Lipid Res. 2011;52:2255-61.
273. Yamada T, Sato J, Okuda Y. Differential affinity of serum amyloid A1 isotypes for high-density lipoprotein. Amyloid. 2009;16:196-200.
274. Yan J, Fu X, Ge F, Zhang B, Yao J, Zhang H, Qian J, Tomozawa H, Naiki H, Sawashita J, Mori M, Higuchi K. Cross-seeding and cross-competition in mouse apolipoprotein A-ll amyloid fibrils and protein A amyloid fibrils. Amer J Path. 2007;171:172-80.
275. Yan SD, Zhu H, Zhu A, Golabek A, Du H, Roher A, Yu J, Soto C, Schmidt AM, Stern D, Kindy M. Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat Med. 2000;6:643-51.
276. Yang Q, Whitin JC, Ling XB, Nayak NR, Cohen HJ, Jin J, Schilling J, Yu TT-S, Madan A. Plasma biomarkers in a mouse model of preterm labor. Ped Res. 2009;66:11-6.
277. Ye RD, Sun L. Emerging functions of serum amyloid A in inflammation. J Leukocyte Biol. 2017;98:923-9.
278. Yoo J-Y, Desiderio S. Innate and acquired immunity intersect in a global view of the acute-phase response. Proc Natl Acad Sci USA. 2003;100:1157-62.
279. Zhang X, Chen J, Wang S. Serum amyloid A induces a vascular smooth muscle cell phenotype switch through the p38 MAPK signaling pathway. BioMed Research Intern ID#4941379; 2017. p. 11.